Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N2586 | Tofacitinib | 0.3 | uM | 3 | b-NGF | 49.0 | 60 | ||||
| N2586 | IKK16 | 2.0 | uM | 3 | b-NGF | 46.0 | 69 | ||||
| N2586 | JNK-IN-8 | 3.0 | uM | 3 | b-NGF | 53.5 | 60 | ||||
| RA2159 | IL-17A | 100 | ng/mL | 3 | b-NGF | 25.0 | 71 | ||||
| RA2159 | PD184352 | 0.1 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 27.0 | 59 | |
| RA2159 | Lestaurtinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 30.0 | 64 | |
| RA2159 | Ruxolitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 28.0 | 70 | |
| RA2159 | Tofacitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 34.0 | 72 | |
| RA2159 | IKK16 | 2.0 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 28.0 | 63 | |
| N2586 | IL-17A | 100 | ng/mL | 3 | b-NGF | 92.5 | 64 | ||||
| N2586 | PD184352 | 0.1 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 80.0 | 54 | |
| N2586 | Lestaurtinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 58.0 | 80 | |
| N2586 | Ruxolitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 113.5 | 50 | |
| N2586 | Tofacitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 51.0 | 66 | |
| N2586 | IKK16 | 2.0 | uM | IL-17A | 100 | ng/mL | 3 | b-NGF | 57.0 | 46 | |
| RA2159 | IL-6 | 100 | ug/mL | 3 | b-NGF | 23.0 | 57 | ||||
| RA2159 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 28.0 | 61 | |
| RA2159 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 26.5 | 50 | |
| RA2159 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 30.0 | 66 | |
| RA2159 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 26.0 | 68 | |
| RA2159 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 30.5 | 48 | |
| RA2159 | Sigma A6730 | 3.0 | uM | 3 | b-NGF | 33.0 | 61 | ||||
| N2586 | IL-6 | 100 | ug/mL | 3 | b-NGF | 87.0 | 67 | ||||
| N2586 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 64.0 | 57 | |
| N2586 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 51.0 | 61 |